Thank you, Mark.
albumin scalability underscoring serum results media meeting applications. and proteins alpha-lactalbumin Our various deliver collaborations recombinant and Dyadic's Dyadic's health wellness culture demonstrate to cell and and we're human market remarkable for position. in and proteins platforms, across ability the consistent, reinforcing producing like alternative biopharmaceuticals Through of uses, critical high-quality for versatility our partnerships, needs these nutritional
and high-value platforms and product revenue, toward positioning Dyadic our costly alternative also our for becoming the achievable of focusing and human continued partners diversifying and complex both health. value the for offerings, markets. and in alternative protein high-value viable on of third strategy and lengthy our developing consumers.
In with is for a essential we of leader as high-demand efficient sustained capabilities seen generate antigens shareholders, in into antibodies, for therapeutics human we By both vaccines. innovations creating Our production animal quarter, products vision and vaccines enable future we're immediate and our biopharmaceutical These animal manufacturing, and advancing expand without growth substantial protein and and and therapeutics near-term production demonstrated development the that
highest market, value and includes X we food alternative key science approach our life recombinant our margin for production. enzymes. segments: refining being proteins proteins by can science, use. are segment processing with life initial products life for tailored and vaccine Dyadic's targeting industrial The and The cell be nutrition highest the and products research-grade Within and science gene various these diagnostics, of nonhuman for offerings markets and research culture majority products category, cell media,
share supplier molecular development partnership is Proliant June, our as recombinant to and commercialization an defined with DNASE-X, cell work proteins in biology.
In nutrition albumin Dyadic market life portfolio research-grade from and threshold serum such the broaden announced additional Proliant's purified albumin, XXXX. science as RNase-free million significant billion serum Dyadic's are a in used of productivity Dyadic of commercialization preparing from The the own strategic quarter, $XXX,XXX launch expanding $X of collaborations, diagnostics, for expected & on markets. fees XXXX. serum on partnership's leading recombinant products including recombinant profits with serum of we albumin our Health will launch reaching animal-free a is research-grade sale Beyond the milestone focus recent of the our we -- focus, this a products, we're upon represents In which culture opportunity applications, products.
To in for first the recombinant and initial in third half received other with human $X Biologics, access albumin anticipated This agreement. and to albumin the first diagnostics product
analysis comparability We demonstrated obtained of have completed the reference a enzyme RNase-free of certificate analytical to initiated with development standards, potential with DNASE-X, customers. sampling and an
We manipulation of enzymes are the revenue in manufacturing to development a biology. DNASE-X multiple producing preorders early segment RNA high-value, our efforts the Alongside molecular in as product. production finalizing now opportunities the product, parties are process a business begin strain, actively XXXX. DNA part and of DNASE-X for and licensing expect is single for essential creating from high-demand interested accepting engaging
plans efforts the regulated clinical-grade future. markets use We our to beyond versions produce are in DNASE-X development this initially segment expanding in for with for research-only
itself We products and DNASE-X RNase of ligases with segments the quarter the have RNA lines anticipated strain and while by sampling DNA X beyond first quarter market. inhibitor additional finalize XXXX, or polymerases, biology optimize penetrate to for in million developed and molecular research-grade cell our broadening products fourth efforts analytics is $XXX we XXXX DNA positioning DNA/RNA late productivity Dyadic comparative the quality. By early and enzymes portfolio,
is cell higher growth proliferation. vitro life cell These the than hormones culture media, initially primary alternative across science needed factors supply development focus healthy recombinant Our growth nutrition Recently, in transfer accelerated essential achieving and strain, for on of nutrients media and pharmaceutical expected. productivity proteins second we the within research, cell and our applications. for
like the of lab-grown and in and captured market This majority completed, food with segment key interest other for expected attractive sampling with particularly the remains application culture This CAGR costs a the and recombinantly. schedule. Dyadic factors certificate applications. being grow analysis of developing research these transferrin $X.X to billion portfolio, has for progress human at With of collaborators and products factors, testing for albumin at and media products media the XXXX. culture cell growth high-value begun of produced markets media over through XX.X% XX% bovine growth our we've of we're meat over global XXXX ahead valued cell and expand in comprising of To
products these us Our initiate partners development exceeding initial testing have of third lines. quarter led time to and to prospective efforts sampling
$XX precision of to health dairy alternative vertical market global consumer nutrition producing are in billion products in starting in XXXX like we're microbial at fermentation, Within valued concerns products our the and preferences Using revenue. lactose the and shifting food response dairy to over animal-free proteins, intolerance. animal-free efforts generate
upfront large-scale, to these a challenges.
Since in surpassed signing production costs positions enzymes, these for and yields first achieving expertise recombinant our in potentially additional $XXX,XXX production our cost-effective high Although agreement to received $XXX,XXX remain with overcome payment XXXX quarter. for protein third the us dairy-derived we've products, commercialize our milestone an non-animal target
ongoing. with to the dairy second enzyme the XXXX aims of development partner a launch in Our half non-animal enzyme first of
with strong have multiple remains alpha-lactalbumin certificate sampling expanding Fermbox, who we're we're pipeline by quarter.
Rounding developed product analysis efforts biofuels, recombinant human of out alpha-lactalbumin the for interest our bovine for enzymes samples. negotiations alpha-lactalbumin evaluated our end and fourth simultaneously third biofuels the products and research-grade in customers. of product advancing alternative precision recently currently with being in commercialize of developing companies with a version we our a with lactoferrin received cellulosic potential applications, bioindustrial with ongoing protein for recombinant our potential value alpha-lactalbumin franchise. to industries set nutrition, We like enzyme targeting segments, quarter, the and Additionally, finalized In the to partnership begin fermentation in biorefining. of Meanwhile, expanding beta-lactoglobulin while
at We months next in has paper to revenue aim Additionally, promising commercialize biofuel the Dyadic growth. designed with applications within and and initially XX production. drive the biogas these enzymes targeted pulp products sector to
near-term mid- to protein human our Mark value revenue As dual and outlined builds emphasizes alternative pharmaceuticals. and animal in long-term strategy in earlier,
antibody CX-produced These XX areas, academia, I protein, completion vaccine Phase successful Since interest standard complex companies. we've fully funded initiated receiving molecules. industry Following projects, first-in-human human to a for ability X including from the XX top government, our we're with disease year, early both and partnerships programs produce, study this and and significant nonprofits. diverse Dyadic's span pharmaceutical health of underscoring over
has HPV, others. seasonal and RSV platform avian expressed including COVID, Mpox, CX antigens, disease and influenza, vaccine malaria, successfully Our multiple infectious HIV,
which our the with engagement WHO, X.X the partnered health formerly our ViroVax monkeypox recently our ferritin per productivity partnered a address days of presentations the by all delivered public from Mpox with of to support leading declared potential outbreak quarter. similar emergency later in those collaborators.
The antibodies suggest health and the antigens this submitted as also an targeting agents, responses, conferences Biotecnopolo cells flu HX human government by demonstrated We from industry, segment. monoclonal a adjuvanted as Siena for shared have interested of ferritin agencies or achieving nanoparticle health grant antibodies collaboration others and Preliminary X spread in actively for evaluation that Mpox Fondazione and nongovernmental CHO a option vaccine our avian gram applications. heightened nonprofits and with testing animal interest findings for di nanoparticle funding antigen liter was has in companies. have animal in help in and activity Multiple influenza a to LLC, made positioning to advance applications variety animal We at international a studies of bird and strong Mpox X flu we LLC third-party been ViroVax with We've immune preclinical human bird develop vaccine ViroVax these organizations human to again medical with for of studies the vaccine the concern this to vaccine. both for number vaccine neutralizing produced further of partners.
To efforts
remain Animal Phibro outbreak, Finally, focused ferritin segment recombinant of for our being for and focused pandemic in partners, In bird including intensified disciplined the the flu the flu animal vaccines Dyadic's product continues development advance light potential technology evaluated on efforts preparedness, collaborations including health to with antigen HX bird poultry key we've business and that's vaccines.
We financially CX-produced expertise. fully leveraging use with cattle nanoparticle on opportunities, Health.
value sustained cover near-term revenue committed entire while animal markets.
With in that, it proteins Our to over alternative our now to Ping growth to Rawson, driving our financials. is in CFO, I'll and team building health human turn
